Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis

被引:75
作者
Latib, Azeem [1 ,2 ,5 ]
Mussardo, Marco [2 ]
Ielasi, Alfonso [2 ]
Tarsia, Giandomenico [4 ]
Godino, Cosmo [1 ,2 ]
Al-Lamee, Rasha [4 ]
Chieffo, Alaide [2 ]
Airoldi, Flavio [3 ]
Carlino, Mauro [2 ]
Montorfano, Matteo [2 ]
Colombo, Antonio [1 ,2 ]
机构
[1] EMO GVM Ctr Cuore Columbus, Intervent Cardiol Unit, I-20145 Milan, Italy
[2] Ist Sci San Raffaele, Intervent Cardiol Unit, I-20132 Milan, Italy
[3] Multimed IRCCS, Intervent Cardiol Unit, Milan, Italy
[4] San Carlo Hosp, Intervent Cardiol Unit, Potenza, Italy
[5] Univ Cape Town, Dept Med, Div Cardiol, ZA-7925 Cape Town, South Africa
关键词
angioplasty; antiplatelet therapy; drug-eluting stent(s); restenosis; stent thrombosis; IMPLANTATION; INTERVENTION;
D O I
10.1016/j.jcin.2010.09.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate the long-term angiographic and clinical outcomes after the treatment of drug-eluting stent in-stent restenosis (DES-ISR) based on the angiographic pattern of restenosis. Background Long-term outcomes after percutaneous treatment of DES-ISR are unclear. Methods This study performed a retrospective analysis of 481 consecutive de novo DES-ISR lesions (n = 392) treated percutaneously between August 2002 and July 2007. The lesions were divided based on the pattern of restenosis: focal (305; 63.4%), diffuse (120; 24.9%), and occlusive (56; 11.6%). Results The majority (65%) of patients had angina or ischemia on presentation and 13% had an acute coronary syndrome. Angiographic follow-up after treatment of DES-ISR was available in 65.5% of lesions. A second angiographic restenosis occurred in 29.1% of the focal group, 45.8% (p = 0.007) of the diffuse, and 65.6% (p < 0.0001) of the occlusive. The pattern of DES-ISR predicted the pattern of recurrence: occlusive reoccluded in 66.7%; diffuse recurred as diffuse or occlusive in 57.9%; focal as focal in 67.2%. During a median follow-up of 2.97 years (interquartile range: 2.37 to 3.89), major adverse cardiac events occurred in 32.8% of patients with no significant differences among the focal, diffuse, and occlusive groups (30.9%, 38.7%, 31.1%; p = 0.38). Diffuse restenosis was associated with a significantly higher target lesion revascularization rate compared with focal (27.1% vs. 15.8%; p = 0.008). A disparity between restenosis (65.6%) and target lesion revascularization (18.5%) rates for occlusive DES-ISR suggests that as many recurrent restenoses were occlusive, they were not retreated. Conclusions DES-ISR identifies a high-risk cohort that is at an increased risk of events, in particular repeat revascularization, during long-term follow-up. The initial pattern of restenosis is the most important predictor of recurrent restenosis or the need for subsequent reintervention. (J Am Coll Cardiol Intv 2011;4:155-64) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:155 / 164
页数:10
相关论文
共 21 条
[1]  
[Anonymous], 1999, Applied Survival Analysis: Time-to-Event
[2]   Treatment of Paclitaxel-Eluting Stent Restenosis With Sirolimus-Eluting Stent Implantation - Angiographic and Clinical Outcomes [J].
Byrne, Robert ;
Iijima, Raisuke ;
Mehilli, Julinda ;
Pache, Juergen ;
Schulz, Stefanie ;
Schoemig, Albert ;
Kastrati, Adnan .
REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (11) :1134-1139
[3]   Bare metal stent restenosis is not a benign clinical entity [J].
Chen, Michael S. ;
John, Jim M. ;
Chew, Derek P. ;
Lee, David S. ;
Ellis, Stephen G. ;
Bhatt, Deepak L. .
AMERICAN HEART JOURNAL, 2006, 151 (06) :1260-1264
[4]   Treatment of Drug-Eluting Stent Restenosis With Another Drug-Eluting Stent: Do Not Fail the Second Time! [J].
Colombo, Antonio ;
Latib, Azeem .
REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (11) :1120-1122
[5]   Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice [J].
Cosgrave, John ;
Melzi, Gloria ;
Corbett, Simon ;
Biondi-Zoccai, Giuseppe G. L. ;
Agostoni, Pierfrancesco ;
Babic, Rade ;
Airoldi, Flavio ;
Chieffio, Alaide ;
Sangiorgi, Giuseppe M. ;
Montorfano, Matteo ;
Michev, Iassen ;
Carlino, Mauro ;
Colombo, Antonio .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (24) :2320-2328
[6]   Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent [J].
Cosgrave, John ;
Melzi, Gloria ;
Corbett, Simon ;
Biondi-Zoccai, Giuseppe G. L. ;
Babic, Rade ;
Airoldi, Flavio ;
Chieffo, Alaide ;
Sangiorgi, Giuseppe M. ;
Montorfano, Matteo ;
Michev, Iassen ;
Carlino, Mauro ;
Colombo, Antonio .
AMERICAN HEART JOURNAL, 2007, 153 (03) :354-359
[7]   Drug-eluting stent restenosis - The pattern predicts the outcome [J].
Cosgrave, John ;
Melzi, Gloria ;
Biondi-Zoccai, Giuseppe G. L. ;
Airoldi, Flavio ;
Chieffo, Alaide ;
Sangiorgi, Giuseppe M. ;
Montorfano, Matteo ;
Michev, Iassen ;
Carlino, Mauro ;
Bonizzoni, Erminio ;
Colombo, Antonio .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (12) :2399-2404
[8]   Clinical end points in coronary stent trials - A case for standardized definitions [J].
Cutlip, Donald E. ;
Windecker, Stephan ;
Mehran, Roxana ;
Boam, Ashley ;
Cohen, David J. ;
van Es, Gerrit-Anne ;
Steg, P. Gabriel ;
Morel, Marie-angele ;
Mauri, Laura ;
Vranckx, Pascal ;
McFadden, Eugene ;
Lansky, Alexandra ;
Hamon, Martial ;
Krucoff, Mitchell W. ;
Serruys, Patrick W. .
CIRCULATION, 2007, 115 (17) :2344-2351
[9]   Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent [J].
Garg, Shaila ;
Smith, Kimberly ;
Torguson, Rebecca ;
Okabe, Teruo ;
Slottow, Tina L. Pinto ;
Steinberg, Daniel H. ;
Roy, Probal ;
Xue, Zhenyi ;
Gevorkian, Natalie ;
Satler, Lowell F. ;
Kent, Kenneth M. ;
Suddath, William O. ;
Pichard, Augusto D. ;
Waksman, Ron .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 70 (01) :9-14
[10]  
Gronnesby J K, 1996, Lifetime Data Anal, V2, P315, DOI 10.1007/BF00127305